aibio
Distress ·
Bioxytran delays annual report as auditor needs more time on 2024 audit
The company filed a late notice for its Form 10-K for the year ended December 31, 2024. It expects to file within the fifteen-day grace period.
BIXT Bioxytran, Inc.
Bioxytran (BIXT) news
Latest Bioxytran news
We have not published a story on Bioxytran yet. When there is news, it will appear here.
What Bioxytran does
Bioxytran, Inc. is a clinical stage pharmaceutical company developing platform technologies in Glycovirology, Hypoxia and Degenerative Diseases, with the stated aim of eliminating viruses and prolonging lifespan using carbohydrate drug design. The company was reorganized into Bioxytran through a reverse merger on September 21, 2018. Four wholly owned subsidiaries handle specific parts of the business, including Pharmalectin, Inc., focused on drugs for viral diseases, and NDPD Pharma, Inc., which works on pharmaceutical manufacturing equipment and on carbohydrate molecules derived from partially hydrolyzed guar gum. The glycovirology platform uses galectin inhibitors against SARS-CoV-2. Its lead candidate, ProLectin-M (PL-M), was evaluated in a randomized, double-blind, placebo-controlled study in patients with mild to moderately severe COVID-19, and the company holds an FDA Investigational New Drug application for it. The hypoxia platform develops an acellular oxygen carrier aimed at brain stroke, wound healing and trauma. Its lead drug candidate, BXT-25, is being developed for stroke treatment and is given intravenously during and after an ischemic stroke.
| Product or program | What it is | Stage |
|---|---|---|
| ProLectin-M (PL-M) | Oral galectin antagonist molecule for mild to moderate COVID-19 | Phase II trial reported; FDA IND approved |
| BXT-25 | Intravenous treatment to keep brain tissue oxygenated during and after ischemic stroke | being developed |
| Acellular Oxygen Carrier (AOC) | Intravenous oxygen carrier for hypoxic conditions and necrosis prevention |
Bioxytran annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $454,000 | $112,337 |
| Net income (loss) | -$2.1 million | -$2.4 million |
| Cash from operations | -$526,455 | -$381,316 |
Questions about Bioxytran
What is the ticker symbol of Bioxytran?
Bioxytran, Inc. trades under the ticker BIXT on OTC.
Where is Bioxytran listed?
Bioxytran, Inc. is listed on OTC.
What is the SEC CIK of Bioxytran?
The SEC Central Index Key (CIK) for Bioxytran, Inc. is 1445815. Its filings are on SEC EDGAR.
How many shares does Bioxytran have outstanding?
114,695,220 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Bioxytran listed under?
Our directory records Bioxytran, Inc. under United States.
What does Bioxytran do?
Our directory classifies Bioxytran, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Bioxytran?
The ISIN recorded for Bioxytran, Inc. is US09075D1028.
Does aibio.space cover Bioxytran?
aibio.space lists Bioxytran, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Bioxytran incorporated?
SEC records list its state or country of incorporation as NV.
What does Bioxytran develop?
Bioxytran, Inc. is a clinical stage pharmaceutical company developing platform technologies in Glycovirology, Hypoxia and Degenerative Diseases, with the stated aim of eliminating viruses and prolonging lifespan using carbohydrate drug design. The company was reorganized into Bioxytran through a reverse merger on September 21, 2018.
What is ProLectin-M (PL-M) from Bioxytran?
ProLectin-M (PL-M): Oral galectin antagonist molecule for mild to moderate COVID-19 Stage: Phase II trial reported; FDA IND approved.
What is BXT-25 from Bioxytran?
BXT-25: Intravenous treatment to keep brain tissue oxygenated during and after ischemic stroke Stage: being developed.
Is Bioxytran profitable?
Bioxytran, Inc. reported a net loss of $2.1 million for the fiscal year ended Dec 31, 2025, and used $526,455 of cash in operations, per its annual report to the SEC.
How much does Bioxytran spend on research and development?
$454,000 in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Bioxytran have?
$23,448 in cash at Sep 30, 2017, per its 10-Q.
Investor discussion: Bioxytran
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Legal
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Bioxytran, Inc
- CIK
- 1445815
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- BIXT (OTC)
- State or country of incorporation
- NV
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- C/O BIOXYTRAN, INC., NEEDHAM, MA, 02494
- Phone
- 617-494-1199
- Shares outstanding
- 114,695,220 as of 2026-08-14 (10-Q filed 2026-08-14)
- Former names
- U.S. RARE EARTH MINERALS, INC.; U.S. RARE EARTH MINERALS, INC; U.S. Natural Nutrients & Minerals, Inc.
Recent filings
Listing details
- Company
- Bioxytran, Inc.
- Ticker
- BIXT
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US09075D1028
- Last quote in directory
- 2026-10-20
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction